MEDDEVICETRACKER

Welcome to Meddevicetracker

Meddevicetracker provides you with real-time analysis of device markets, companies and products through a flexible user interface, allowing you to quickly find the information and analysis you need to make strategic business decisions.

This Quick Start guide will show you how to:



1 Getting started: How to log in

To log in to Meddevicetracker visit www.meddevicetracker.com/login.cfm

Getting started: Logged in home page

Once you have entered a valid user name and password you'll be taken to the product home page.





а

Getting started: Navigation

06

Informa Pharma Intelligence Legacy Meddevicetracker	Welcome Jocelyn August Training Lagout
Meddevicetracker Search All - Enter a Company, Indication, Product, etc Pharma Intelligence Pharma Intelligence	Q Advanced Search 🗸 Resources 🗸 🔩 Ask the Analyst
A Upcoming Catalysts Impact Events Products Companies Indications	Market Analysis Report Library More -
LATEST MEDDEVICETRACKER ANALYSIS	6 7
Asahi Kasei Corporation (AHKSY) 06/18/2019	10 million and a second
Zoll Zeroes In On TherOx, Acquires SSO2 Therapy	Meddevicetracker 📎
TherOx DownStream System for Cardiac Arrest/Resuscitation	Pharma Intelligence
Zoll Medical Corp. has acquired TherOx Inc. following the US FDA approval of TherOx's SuperSaturated Oxy (SSO2) Therapy for heart-attack patients. Financial terms of the transaction were not disclosed. TherOx's Therapy is an electromechanical device that delivers supersaturated oxygen directly to the damaged part heart immediately after a coronary intervention to reduce the size of the extent of damage caused by a r infarction. Using a disposable cartridge with a three-chambered body, the SSO2 solution is created from in Re	ygen SSO2 t of the myocardial nput ead More >
EVENTS & CATALYSTS	
Ton-Line Date Events Latest Regulatory Events High Impact Events Ton-Line Data Catalysts	Regulatory Catalysts Large Impact Catalysts
Date Load Company Direct State Company	
07/01/2019 Avita Medical (AVMXE) RECELL Device for Diabetic Foot and Other Licers	Trial Data - Top-Line Results
06/24/2019 Micro Medical Solutions Micro Stept for Peripheral Arterial Disease (PAD)	Trial Data - Top-Line Results
06/15/2019 SetPoint SetPoint Implantable Neuromodulation Device for Rheu	matoid Arthritis (RA) Trial Data - Top-Line Results
06/14/2019 Admedus (AMEUF) CardioCel for Congestive Heart Failure (CHF) and Cardion	nyopathies Trial Data - Published Results
06/13/2019 Philips (PHG) REMstar Auto with A-Flex for Airway Management	Trial Data - Published Results
	Mare >

- 1 Upcoming Catalysts- Search on over 100 catalyst types
- 2 Impact Events Search on over 100 event types
- **3 Products** Search on over 8,000 products
- 4 **Companies** Search on over 2,000 companies
- 5 Indications View a competitive landscape of devices and diagnostics by indication or disease area
- 6 Market Analysis- Search for detailed market and competitor analysis by device type
- 7 **Reports** Over 300 comprehensive global medtech market reports



Finding content: Quick Search

Easily find what you are looking for by using the intuitive quick search – click on the autocomplete result to go directly to the page requested, or press enter to search for all.

Search All 🔻	ellipta		Q
	Ellipta I haler	→ Product	
Impact Event	Arnuity Ellipta Inhaler (Ellipta Inhaler)	→ Product	arket Analy
	Relegy Ellipta Inhaler (Ellipta Inhaler)	→ Product	
	Anoro Ellipta Inhaler (Ellipta Inhaler)	→ Product	
	Breo Ellipta Inhaler (Ellipta Inhaler)	→ Product	
	Incruse Ellipta Inhaler (Ellipta Inhaler)	→ Product	
nort -	Search more	>	

5 Finding content: Search by catalyst/product/event

0.00

You can choose to run advanced searches by catalysts, products, events, combination products or trials.

Results can be fi ltered and refi ned to meet your research requirements. In addition, you will be able to navigate to the Market Analysis sections for more detailed insight.



Finding content: Search by product AND indication

You can search across the entire database for products by both product type and indication. From the indication report, use the drop down filtering functionality for Type to select or filter by product type.

а

Coronary Artery Disease

Narrowing or blockage of one or more of the coronary arteries resulting in decreased blood supply to the heart (ischemia).

....

Product Pipeline

			Search:	stent
Clinical Analysis (Last ÷ Event)	Product Name 🔹	Lead Company +	Type +	Phase ÷
Feb 11, 2016	ABLUMINUS Sirolimus-Eluting Stent System	Envision Scientific Pvt. Ltd.	Drug-Eluting Stents	Development Outside U.S.
Apr 12, 2017	Abrax Sirolimus-Euting Stent System	Rontis Corporation	Drug-Eluting Stents	Development Outside U.S.
Sep 25, 2018	ABSORB BVS	Abbott Laboratories (ABT)	Bioabsorbable Stents/Scaffolds	Withdrawn from Market
Oct 31, 2017	Amaranth FORTITUDE	Amaranth Medical, Inc.	Bioabsorbable Stents/Scaffolds	Development Outside U.S.
May 31, 2018	Amazonia SIR	STENTYS SA (STNT:FP)	Drug-Eluting Stents	Approved in Europe
Oct 31, 2016	AMITY	Elixir Medical Corporation	Drug-Eluting Stents	Development Outside U.S.

Once you click into the Product type you are interested in, you will be able to view all products that fall into that product type classification. In addition, you will be able to navigate to the Market Forecast section.

Market Analysis 🗧 🕻	
Description	Stanta
Pipeline Chart	Stenits
Competitive Analysis	Product Type
Procedure Volumes	Device L-Circulatory Disorder Management Devices
Product Pipeline	i-Stents -Drug-Eluting Stents
Market Forecast	Bare Metal Stents Covered Stents/Stent Grafts
Reports	L_Bloabsorbable Stents/Scaffolds
	Description
	Coronary Stents
	Coronary stents—thry bolloon-expandable or self-expanding scaffolds—are placed within narrowed/occluded arteries in the heart to maintain or restore vessel potency. The development of these devices revolutionized catheter-based interventions for coronary heart disease (HD). Not only are coronary stents effective in reducing the rate of restensis and other complications associated with PTCA, they also have proven useful as a direct interventional therapy (e.g., for treating short, first-time lesions in large artifies and for opening occluded bypass grafts). Advancements in stenting technologies have continued to reduce restensis rates following PC (procedures, allowing the modality to be used in an ever larger percentage of patients who in the past would have been condidates for highly invasive CABG surgery.
	Types of Coronary Stents

Market Forecast

Last Update: 05/03/2016

Coronary Stenting

In the U.S., the total market for coronary stents is projected to decline slightly at a compound annual rate of 0.1% during the forecast period covered by this analysis, decreasing in value from approximately \$1,783.2 million in 2015 to an estimated \$1,774.9 million in the year 2020. Over the next half-decade, DES sales in the U.S. are forecast to decrease at a compound annual rate of 0.1%, declining from approximately \$1,700.0 million in 2015 to an estimated \$1,695.0 million in the year 2020. During this same period, BMS sales in the U.S. are expected to decline at a compound annual rate of 0.8%, falling from approximately \$83.2 million in 2015 to an estimated \$79.9 million in the year 2020.

Factors that will constrain sales in the U.S. coronary stents market over the next half-decade include:

000

- clinician caution engendered by charges of stent overuse;
- a focus on medical management in lower risk patients;
- · adoption of FFR to determine idela patients for stent placement, eliminating unnecessary stenting procedures;
- utilization of alternative revascularization technologies (e.g., drug-eluting balloons); and,
- price erosion as a result of over-saturation from various stent developers.

Factors that could potentially improve coronary stent sales include:

- improvements in stent designs and materials, specifically in bare-metal stents; and,
- positive long-term clinical data supporting the use of bioresorbable stents, which are expected to be priced as premium products.

Exhibit MA-1 presents the U.S. market forecast for coronary stents for the years 2015 through 2020.

Exhibit MA-1: Coronary Stents, Market Forecast, 2015-2020

Products	2015	2016	2017	2018	2019	2020	CAGR (2015-2020)
Bare-Metal Stenting: Bare-Metal Stenting Procedures Bare-Metal Stentis Placed Average Device Price Subtotal Bare-Metal Stent System Sales	97.4 136.3 \$610.2 \$83.2M	97.8 135.5 \$609.3 \$82.6M	98.3 134.9 \$607.8 \$82.0M	98.8 134.2 \$605.6 \$81.3M	99.3 133.6 \$603.5 \$80.6M	99.9 133.0 \$601.1 \$79.9M	0.5% -0.5 -0.3 -0.8 %
Drug-Eluting Stenting: Drug-Eluting Stenting Procedures Drug-Eluting Stents Placed Average Device Price Subtotal Drug-Eluting Stent System Sales	836.4 1,204.0 \$1,411.5 \$1,700.0M	840.6 1,208.0 \$1,408.7 \$1,701.6M	845.6 1,210.0 \$1,406.0 \$1,704.6M	851.5 1,213.0 \$1,402.0 \$1,700.5M	858.4 1,215.0 \$1,397.0 \$1,698.6M	866.9 1.218.0 \$1391.8 \$1,695.0	0.7% 0.2 -0.3 -0.1%
Total Coronary Stenting Procedures	933.8	938.4	943.9	950.3	957.7	966.8	0.7%
Total Coronary Stents Placed	1,340.8	1,343.5	1,344.9	1,347.2	1,348.6	1,351.0	0.2%
Total Coronary Stent System Sales	\$1,783.2M	\$1,784.2M	\$1,783.4M	\$1,781.7M	\$1,779.2M	\$1,774.9M	-0.1%

steps. Stents placed per procedure is an average based on the number of stents used in the treatment of single- and multi-vessel cases. Average stents placed are reported in thousands. Procedure volumes are reported in thousands.



0.69

On the home page click on the Reports tab.



You can also find relevant published reports in the Market Analysis by Product Type pages – just use the left side navigation to jump to the Reports section.

Reports				
Report Title	Date Published			
Interventional Neurology: Carotid Artery Stents and Embolic Protection Systems	12/18/2018			
Interventional Cardiology: Vascular Stents	01/25/2018			
U.S. Markets for Interventional Cardiology Products, April 2016	04/01/2016			
U.S. Markets for Stroke Management, August 2015	08/03/2015			
U.S. Markets for Neurosurgical and Neurointerventional Products, September 2014	09/01/2014			

You can browse the report and use the contents list in the left menu to navigate.



Go To My Library View Report Gallery

Interventional Cardiology: Vascular Stents

The global market for vascular stents is being driven by the increasing prevalence of cardiovascular disease (CVD). CVD is the leading cause of death globally, responsible for over 17 million deaths annually. This analysis includes a discussion of products, current/forecast markets, competitors, and opportunities in the global vascular stents products market, which includes bare-metal stents (BMSs), drug-eluting stents (DESs), and bioresorbable vascular stents/scoffolds (BVSs). Primary research querying interventional cardiologists regarding device preferences and vascular stent stillization was leveraged in the formulation of this report's forecasts and analyses. Global product sales are projected to expand at a compound annual growth rate (CAGR) of 6.2% during 2016-21, increasing from approximately 56,535.3m in 2016 to an estimated 58,827.1m in 2021. Countries/regions covered by this report include the US, five major European markets (France, Germany, Italy, Spain, and the UK), Japan, and the Rest of the World segment (which combines estimated sales data for all other countries).



Search Bookmarks...

Executive Summary

C. Vascular Stent Products

Exhibit 2-1: Advantages and dls

2.1 Vascular stent products

2.2 Vascular stent products

2.2.2 Vascular stents in developm

2.3 Trends in vascular stent inn

- -2.4 Alternatives to vascular ste
- 2.5 Bibliography
- -3. Vascular Stents Market
 - + 3.2 Global competitors
 - 3.3 Market forecast
 - -3.4 Bibliography
- -Company Listing

Interventional Cardiology: Vascular Stents

Executive Summary

This comprehensive medical market and technology report provides an overview and in-depth market analysis of vascular stents, specifically bare-metal stents (BMSs) and drug-eluting stents (DESs) used in the treatment of severe coronary artery disease (CAD) and peripheral artery disease (PAD). In addition, this report provides analysis of the developing bioresorbable vascular scaffold (BVS), or fully biodsorbable stent market.

- The report provides the following useful information:
- an overview of cardiovascular diseases (CVDs)
- key statistics on selected CVDs in major regions in the world
- medical device product portfolios offered by manufacturers
- insight into developing and potentially disruptive technologies
- in-depth market and competitive analysis.

i. Cardiovascular diseases overview

CVD, which is a general classification for diseases involving the blood vessels and/or heart, can be caused by a variety of risk factors depending on the type of CVD. CVDs are the leading cause of death globally, and are responsible for over 17 million deaths annually. Managing and lowering the individual impact of risk factors is the key to preventing CVD and reducing its burden.

This report provides key statistics on selected types of CVD, including: acute coronary syndrome, hypertension, cardiomyopathies, congenital heart defects, heart failure, peripheral vascular disease, and cerebrovascular disease.

https://www.citeline.com/en/productsservices/commercialization/meddevicetracker Email: clientservices@citeline.com

